Haemonetics (HAE) Proxy Filing summary

Executive summary

• Annual meeting scheduled for July 25, 2024, to elect nine directors, approve executive compensation, and ratify Ernst & Young LLP as auditor for fiscal 2025.

• Fiscal 2024 saw strong demand, double-digit revenue growth, and strategic acquisitions, with continued focus on operational excellence and portfolio rationalization.

• Board and management emphasize ESG, corporate responsibility, and active shareholder engagement, with regular outreach and transparent disclosures.

Voting matters and shareholder proposals

• Shareholders will vote on director elections, executive compensation (say-on-pay), and auditor ratification.

• Board recommends voting FOR all proposals.

• Shareholder proposals for the 2025 meeting must be submitted by February 7, 2025.

Board of directors and corporate governance

• Board consists of nine members, eight of whom are independent, with a diverse mix of skills and backgrounds.

• Annual board and committee self-evaluations, peer reviews, and a retirement policy at age 75 support board refreshment.

• Four standing committees: Audit, Compensation, Governance and Compliance, and Technology, all composed of independent directors.

• Board Chair is independent and separate from the CEO.

• Shareholder rights include majority voting, right to call special meetings, and no poison pill.